{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:28:38Z","timestamp":1768782518950,"version":"3.49.0"},"reference-count":29,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>High-grade serous ovarian cancer (HGSOC) is an aggressive malignancy which is often treated with platinum-based chemotherapy and PARP inhibitors (PARPi). However, PARPi resistance remains a major clinical challenge, necessitating alternative therapeutic strategies. In this study, we establish the first known patient-derived organoid models directly from PARPi-resistant HGSOC and demonstrate that they preserve the original tumor architecture and key biomarkers (EpCAM, CA125, PAX8, HER2, MEK1\/2, Cyclin E1), thus providing unique preclinical models for drug testing. These organoids were used to evaluate lurbinectedin in comparison with standard carboplatin and paclitaxel. While lurbinectedin showed comparable apoptotic effects to paclitaxel and superior activity to carboplatin, it induced chromosomal breaks to different extents in different cell lines, suggesting a distinct mechanism of action. Importantly, this work does not advocate for lurbinectedin as a superior therapy but, rather, demonstrates the utility of organoid models in uncovering drug-specific genomic effects. Our findings underscore the critical need for expanded testing using clinically relevant models to identify more effective strategies against PARPi-resistant disease.<\/jats:p>","DOI":"10.3390\/ijms26188866","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T15:10:46Z","timestamp":1757603446000},"page":"8866","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Effects of Lurbinectedin in PARP Inhibitor-Resistant High-Grade Serous Ovarian Cancer Using Patient-Derived Cell Lines and Organoid Models"],"prefix":"10.3390","volume":"26","author":[{"given":"Akshi","family":"Srivastava","sequence":"first","affiliation":[{"name":"Translational Gynecology Group, Department of Obstetrics and Gynecology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Unterweger","sequence":"additional","affiliation":[{"name":"Translational Gynecology Group, Department of Obstetrics and Gynecology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1976-0838","authenticated-orcid":false,"given":"Sarah","family":"Guttmann","sequence":"additional","affiliation":[{"name":"Translational Gynecology Group, Department of Obstetrics and Gynecology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Wolf","sequence":"additional","affiliation":[{"name":"Translational Gynecology Group, Department of Obstetrics and Gynecology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3399-078X","authenticated-orcid":false,"given":"Leonhard","family":"M\u00fcllauer","sequence":"additional","affiliation":[{"name":"Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7017-5426","authenticated-orcid":false,"given":"Martin","family":"Schepelmann","sequence":"additional","affiliation":[{"name":"Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Cacsire Castillo-Tong","sequence":"additional","affiliation":[{"name":"Translational Gynecology Group, Department of Obstetrics and Gynecology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1938-1574","authenticated-orcid":false,"given":"Thomas","family":"Bartl","sequence":"additional","affiliation":[{"name":"Translational Gynecology Group, Department of Obstetrics and Gynecology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: An overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: Final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Leary","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_3","first-page":"367","article-title":"Homologous recombination deficiency in epithelial ovarian cancer","volume":"13","author":"Bartl","year":"2020","journal-title":"Memo-Mag. Eur. Med. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/nsmb.1915","article-title":"Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination","volume":"17","author":"Buisson","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Doig, K.D., Fellowes, A.P., and Fox, S.B. (2023). Homologous recombination repair deficiency: An overview for pathologists. Mod. Pathol., 36.","DOI":"10.1016\/j.modpat.2022.100049"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1038\/s41467-024-46999-x","article-title":"Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: The randomized phase II NeoPembrOV clinical trial","volume":"15","author":"Savoye","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Romeo, M., Gil-Mart\u00edn, M., Gaba, L., Teruel, I., Taus, \u00c1., Fina, C., Masvidal, M., Murata, P., Fern\u00e1ndez-Plana, J., and Mart\u00ednez, A. (2022). Multicenter real-world data of subsequent chemotherapy after progression to PARP inhibitors in a maintenance relapse setting. Cancers, 14.","DOI":"10.3390\/cancers14184414"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole\u2013genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1158\/2159-8290.CD-19-1485","article-title":"Clinical BRCA1\/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance","volume":"10","author":"Pettitt","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ygyno.2021.08.032","article-title":"Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)","volume":"163","author":"Gaillard","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1476-5381.2010.00945.x","article-title":"PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity","volume":"161","author":"Leal","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/ijgc-2022-003764","article-title":"Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: A real-life case\u2013control study","volume":"33","author":"Vertechy","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.3802\/jgo.2023.34.e57","article-title":"Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: A Delphi consensus","volume":"34","author":"Redondo","year":"2023","journal-title":"J. Gynecol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"de Witte, C.J., Valle-Inclan, J.E., Hami, N., L\u00f5hmussaar, K., Kopper, O., Vreuls, C.P.H., Jonges, G.N., van Diest, P., Nguyen, L., and Clevers, H. (2020). Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter-and intrapatient drug responses. Cell Rep., 31.","DOI":"10.1016\/j.celrep.2020.107762"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","article-title":"An organoid platform for ovarian cancer captures intra-and interpatient heterogeneity","volume":"25","author":"Kopper","year":"2019","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Battistini, C., and Cavallaro, U. (2023). Patient-derived in vitro models of ovarian cancer: Powerful tools to explore the biology of the disease and develop personalized treatments. Cancers, 15.","DOI":"10.3390\/cancers15020368"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Nero, C., Vizzielli, G., Lorusso, D., Cesari, E., Daniele, G., Loverro, M., Scambia, G., and Sette, C. (2021). Patient-derived organoids and high grade serous ovarian cancer: From disease modeling to personalized medicine. J. Exp. Clin. Cancer Res., 40.","DOI":"10.1186\/s13046-021-01917-7"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.canlet.2015.03.040","article-title":"Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer","volume":"362","author":"Kreuzinger","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2019.05.032","article-title":"Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer","volume":"459","author":"Kreuzinger","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.stem.2018.11.011","article-title":"Phenotypic plasticity: Driver of cancer initiation, progression, and therapy resistance","volume":"24","author":"Gupta","year":"2019","journal-title":"Cell Stem Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","article-title":"Organoids in cancer research","volume":"18","author":"Drost","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2011.07.050","article-title":"Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett\u2019s epithelium","volume":"141","author":"Sato","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","article-title":"Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids","volume":"8","author":"Hill","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1158\/1078-0432.CCR-12-1513","article-title":"Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer","volume":"18","author":"Vidal","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Poveda, A., Lopez-Reig, R., Oaknin, A., Redondo, A., Rubio, M.J., Guerra, E., Fari\u00f1as-Madrid, L., Gallego, A., Rodriguez-Freixinos, V., and Fernandez-Serra, A. (2022). Phase 2 trial (POLA Study) of lurbinectedin plus olaparib in patients with advanced solid tumors: Results of efficacy, tolerability, and the translational study. Cancers, 14.","DOI":"10.3390\/cancers14040915"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid modeling of the tumor immune microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41568-018-0018-3","article-title":"Organoid diversity","volume":"18","author":"Dart","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: Recommendations for improving outcomes","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nat. Rev. Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/18\/8866\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:44:12Z","timestamp":1760035452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/18\/8866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":29,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijms26188866"],"URL":"https:\/\/doi.org\/10.3390\/ijms26188866","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]}}}